Elena Valassi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4245863/publications.pdf

Version: 2024-02-01

79 papers

2,814 citations

218381 26 h-index 51 g-index

80 all docs 80 docs citations

80 times ranked

2808 citing authors

#	Article	IF	CITATIONS
1	Complication Rates after Endoscopic Transsphenoidal Surgery for ACTH-Secreting Pituitary Adenomas: A Comparative Analysis with GH and Nonfunctioning Adenomas. Journal of Neurological Surgery, Part B: Skull Base, 2022, 83, e274-e283.	0.4	1
2	Pituitary Society Delphi Survey: An international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. Pituitary, 2022, 25, 64-73.	1.6	7
3	Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response. Biomedicines, 2022, 10, 460.	1.4	7
4	Clinical presentation and etiology of Cushing's syndrome: Data from <scp>ERCUSYN</scp> . Journal of Neuroendocrinology, 2022, 34, .	1.2	25
5	Consequences of Cushing's syndrome: Health versus personal costs. Journal of Clinical Endocrinology and Metabolism, 2022, , .	1.8	1
6	Data mining analyses for precision medicine in acromegaly: a proof of concept. Scientific Reports, 2022, 12, .	1.6	11
7	Unmet needs in Cushing's syndrome: the patients' perspective. Endocrine Connections, 2022, 11, .	0.8	6
8	Quality of life impairment after a diagnosis of Cushing's syndrome. Pituitary, 2022, 25, 768-771.	1.6	10
9	Molecular determinants of enhanced response to somatostatin receptor ligands after debulking in large GHâ€producing adenomas. Clinical Endocrinology, 2021, 94, 811-819.	1.2	9
10	Quality of life in Cushing's syndrome. Best Practice and Research in Clinical Endocrinology and Metabolism, 2021, 35, 101505.	2.2	16
11	Quality of life in pituitary tumors. , 2021, , 669-677.		O
12	PatologÃa hipofisaria y gestación. Endocrinologia, Diabetes Y NutriciÓn, 2021, 68, 184-195.	0.1	3
13	Pituitary disease and pregnancy. Endocrinolog $ ilde{A}$ a Diabetes Y Nutrici $ ilde{A}$ 3n (English Ed), 2021, 68, 184-195.	0.1	3
14	Corticotroph tumor progression after bilateral adrenalectomy (Nelson's syndrome): systematic review and expert consensus recommendations. European Journal of Endocrinology, 2021, 184, P1-P16.	1.9	32
15	Intramuscular fatty infiltration and physical function in controlled acromegaly. European Journal of Endocrinology, 2021, 185, 167-177.	1.9	7
16	Prevalence of sarcopenia after remission of hypercortisolism and its impact on HRQoL. Clinical Endocrinology, 2021, 95, 735-743.	1.2	8
17	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	5.5	315
18	Time to Diagnosis in Cushing's Syndrome: A Meta-Analysis Based on 5367 Patients. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e12-e22.	1.8	69

#	Article	IF	Citations
19	Thigh Muscle Fat Infiltration Is Associated With Impaired Physical Performance Despite Remission in Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2039-e2049.	1.8	17
20	Psychiatric and neurocognitive consequences of endogenous hypercortisolism. Journal of Internal Medicine, 2020, 288, 168-182.	2.7	35
21	Patient-Centered Outcomes with Pituitary and Parasellar Disease. Neuroendocrinology, 2020, 110, 882-888.	1.2	9
22	Molecular profiling for acromegaly treatment: a validation study. Endocrine-Related Cancer, 2020, 27, 375-389.	1.6	39
23	Quality of Life in Patients With Cushing's Disease. Frontiers in Endocrinology, 2019, 10, 862.	1.5	28
24	Circulating miR-103a-3p and miR-660-5p are associated with bone parameters in patients with controlled acromegaly. Endocrine Connections, 2019, 8, 39-49.	0.8	15
25	High mortality within 90 days of diagnosis in patients with Cushing's syndrome: results from the ERCUSYN registry. European Journal of Endocrinology, 2019, 181, 461-472.	1.9	53
26	MON-LB073 The Serum Creatinine to Serum Cystatin C Ratio Is a Reliable Surrogate Marker of Sarcopenia in Patients with Cushing's Syndrome in Remission. Journal of the Endocrine Society, 2019, 3, .	0.1	0
27	MON-LB074 Ultrasonography May Reliably Assess Muscle Architecture in Patients with Cushing's Syndrome in Remission: Comparison with Gold-Standard Muscle MRI. Journal of the Endocrine Society, 2019, 3, .	0.1	0
28	Quality of life in patients with pituitary tumors. Current Opinion in Endocrine and Metabolic Research, 2018, 1, 67-73.	0.6	1
29	Morbidity of Cushing's Syndrome and Impact ofÂTreatment. Endocrinology and Metabolism Clinics of North America, 2018, 47, 299-311.	1.2	22
30	Worse Healthâ€Related Quality of Life at longâ€term followâ€up in patients with Cushing's disease than patients with cortisol producing adenoma. Data from the <scp>ERCUSYN</scp> . Clinical Endocrinology, 2018, 88, 787-798.	1.2	40
31	Quality of Life in Cushing's disease: A long term issue?. Annales D'Endocrinologie, 2018, 79, 132-137.	0.6	22
32	Preoperative medical treatment in Cushing's syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN. European Journal of Endocrinology, 2018, 178, 399-409.	1.9	37
33	MANAGEMENT OF ENDOCRINE DISEASE: Quality of life tools for the management of pituitary disease. European Journal of Endocrinology, 2017, 177, R13-R26.	1.9	37
34	Diagnostic tests for Cushing's syndrome differ from published guidelines: data from ERCUSYN. European Journal of Endocrinology, 2017, 176, 613-624.	1.9	42
35	Long-Term Effects of Prior Cushing's Syndrome. , 2017, , 199-224.		0
36	Affective alterations in patients with Cushing's syndrome in remission are associated with decreased BDNF and cortisone levels. European Journal of Endocrinology, 2017, 176, 221-231.	1.9	28

#	Article	lF	CITATIONS
37	A polymorphism in the <i>CYP17A1</i> gene influences the therapeutic response to steroidogenesis inhibitors in Cushing's syndrome. Clinical Endocrinology, 2017, 87, 433-439.	1.2	19
38	Cystatin-C and epicardial adipose tissue as noninvasive predictors of cardiovascular risk in acromegaly. Clinical Endocrinology, 2017, 86, 214-222.	1.2	9
39	Update on quality of life in patients with acromegaly. Pituitary, 2017, 20, 185-188.	1.6	35
40	Cushing's syndrome and pregnancy outcomes: a systematic review of published cases. Endocrine, 2017, 55, 555-563.	1.1	87
41	Depression and Anxiety Scores Are Associated with Amygdala Volume in Cushing's Syndrome: Preliminary Study. BioMed Research International, 2017, 2017, 1-7.	0.9	19
42	Epicardial fat is a negative predictor of spine volumetric bone mineral density and trabecular bone score in acromegaly. Endocrine, 2016, 53, 860-864.	1.1	10
43	El Registro Molecular de Adenomas Hipofisarios (REMAH): una apuesta de futuro de la EndocrinologÃa espaA±ola por la medicina individualizada y la investigación traslacional. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2016, 63, 274-284.	0.8	18
44	The Molecular Registry of Pituitary Adenomas (REMAH): A bet by Spanish Endocrinology for the future of individualized medicine and translational research. EndocrinologÃa Y Nutrición (English Edition), 2016, 63, 274-284.	0.5	13
45	Reduction of trabecular and cortical volumetric bone mineral density at the proximal femur in patients with acromegaly. European Journal of Endocrinology, 2016, 174, 107-114.	1.9	15
46	Dyslipidemia and Chronic Inflammation Markers Are Correlated with Telomere Length Shortening in Cushing's Syndrome. PLoS ONE, 2015, 10, e0120185.	1.1	39
47	Health-Related Quality of Life in Pituitary Diseases. Endocrinology and Metabolism Clinics of North America, 2015, 44, 161-170.	1.2	29
48	Impaired decision making and delayed memory are related with anxiety and depressive symptoms in acromegaly. Endocrine, 2015, 50, 756-763.	1.1	33
49	Cardiovascular risk and white matter lesions after endocrine control of Cushing's syndrome. European Journal of Endocrinology, 2015, 173, 765-775.	1.9	35
50	Impaired decisionâ€making and selective cortical frontal thinning in Cushing's syndrome. Clinical Endocrinology, 2014, 81, 826-833.	1.2	46
51	Telomere length analysis in Cushing's syndrome. European Journal of Endocrinology, 2014, 171, 21-29.	1.9	25
52	Prognosis of patients treated for Cushing syndrome. Endocrinolog \tilde{A} a Y Nutrici \tilde{A}^3 n (English Edition), 2014, 61, 52-61.	0.5	9
53	Small cerebellar cortex volume in patients with active Cushing's syndrome. European Journal of Endocrinology, 2014, 171, 461-469.	1.9	55
54	PronÃ ³ stico del paciente tratado de sÃndrome de Cushing. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2014, 61, 52-61.	0.8	13

#	Article	IF	CITATIONS
55	Acromegalia y gestaci \tilde{A}^3 n. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2013, 60, 1-3.	0.8	8
56	Adipokines and Cardiovascular Risk in Cushing's Syndrome. Neuroendocrinology, 2012, 95, 187-206.	1.2	47
57	A reappraisal of the medical therapy with steroidogenesis inhibitors in <scp>C</scp> ushing's syndrome. Clinical Endocrinology, 2012, 77, 735-742.	1.2	83
58	Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice. European Journal of Endocrinology, 2012, 167, 337-342.	1.9	50
59	Clinical consequences of Cushing's syndrome. Pituitary, 2012, 15, 319-329.	1.6	50
60	The value of a European registry for pituitary adenomas: The example of Cushing's syndrome registry. Annales D'Endocrinologie, 2012, 73, 83-89.	0.6	6
61	The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. European Journal of Endocrinology, 2011, 165, 383-392.	1.9	322
62	Delayed Remission after Transsphenoidal Surgery in Patients with Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 601-610.	1.8	133
63	Potential Cardiac Valve Effects of Dopamine Agonists in Hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1025-1033.	1.8	122
64	Improving Quality of Life in Patients with Pituitary Tumours. European Endocrinology, 2010, 9, 32.	0.8	7
65	Neuroendocrine control of food intake. Nutrition, Metabolism and Cardiovascular Diseases, 2008, 18, 158-168.	1.1	522
66	Increased serum levels of the Wnt antagonist Dicckopf-1 (DKK1) and impaired trabecular bone mineral density using QCT scan in acromegalic patients. Endocrine Abstracts, 0, , .	0.0	0
67	Serum brain-derived neurotrophic factor in Cushing[apos]s syndrome patients. Endocrine Abstracts, 0, , .	0.0	0
68	Psychopathology, memory and quality of life in Cushing's syndrome. Endocrine Abstracts, 0, , .	0.0	0
69	Relationship between circulating microRNAs and bone mineral density in patients with active acromegaly. Endocrine Abstracts, 0, , .	0.0	0
70	Diabetes mellitus and muscle weakness are independently associated with mortality in patients with Cushing's syndrome. Data from ERCUSYN. Endocrine Abstracts, 0, , .	0.0	0
71	Molecular profiling of non-functioning pituitary adenomas does not support pharmacological therapeutic options. Endocrine Abstracts, 0, , .	0.0	0
72	Psychopathology in Cushing's disease and acromegaly. Endocrine Abstracts, 0, , .	0.0	0

#	Article	lF	Citations
73	Muscle dysfunction is associated with poor quality of life in patients with Cushing's syndrome long-term after remission. Endocrine Abstracts, 0, , .	0.0	0
74	Skeletal muscle fatty infiltration in the thigh, as assessed by MRI T2-weighted and 3-point Dixon sequences, is associated with poor performance on muscle function testing in patients with Cushing's syndrome in remission. Endocrine Abstracts, 0, , .	0.0	0
75	European observational study of ketoconazole for endogenous cushing's syndrome in collaboration with European registry on cushing's syndrome ERCUSYN: PASS ketoconazole study design and rationale. Endocrine Abstracts, 0, , .	0.0	0
76	Data mining analyses for precision medicine in acromegaly. Endocrine Abstracts, 0, , .	0.0	0
77	The cushing's collaborative patient survey results. Endocrine Abstracts, 0, , .	0.0	0
78	Etiology and extent of impaired quality of life, fatigue and affective, cognitive, and emotional dysfunction in patients with cushing $\hat{a} \in \mathbb{N}$ syndrome $\hat{a} \in \mathbb{N}$ The IQFACE-CS study. Endocrine Abstracts, 0, , .	0.0	0
79	Gender dimorphism of intramuscular fatty infiltration and related muscle dysfunction in patients with long-term control of acromegaly. Endocrine Abstracts, 0, , .	0.0	0